Biotech | January 11, 2022
Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
It is the generic version of molnupiravir
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Subscribe To Our Newsletter & Stay Updated
